You have committed to peptide therapy for weight loss. The vial or pen is in your hands. The big question: when exactly will the kilograms start dropping? Below is a realistic month-by-month timeline from first injection to sustained results. You will find specific numbers, typical sensations at each stage, and strategies to maximize your progress.

This practical timeline draws on clinical trial data for tirzepatide (SURMOUNT program, n=2,539) and retatrutide (Phase II, n=338). Numbers are averages; your individual pace depends on starting weight, dose titration schedule, and metabolic profile. Your result can be above or below these averages — that is completely normal.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before starting any peptide protocol. Peptex supplies research peptides; responsibility for use lies with the buyer.

Week 0 — Establishing Your Baseline

Before the first injection, record your starting metrics. Without them, three months later you will have no objective way to measure progress — self-perception of body changes is unreliable.

• Fasted morning weight (no clothing), on the same day each week
• Waist circumference at navel level and hip measurement
• Progress photos from three angles under consistent lighting (front, side, back)
• A 3–5 day food diary — you will use it to compare appetite changes around weeks 2–3
• Baseline bloodwork: fasting glucose, HbA1c, lipid panel, TSH. These will reveal metabolic improvements over time

Starting dose of tirzepatide is 2.5 mg weekly. Retatrutide starts at 1 mg. The low starting dose is about GI adaptation, not weight loss. Do not escalate during the first four weeks — it only increases nausea without additional fat-loss benefit.

Month 1: Adaptation & Early Signals (Weeks 1–4)

What happens inside

Tirzepatide simultaneously activates GIP and GLP-1 receptors, slowing gastric emptying and acting on satiety centers in the hypothalamus. Food stays in the stomach longer, fullness arrives faster and lasts for hours. Retatrutide adds glucagon receptor activation, enhancing fat breakdown in the liver and adipose tissue — an effect absent in dual agonists.

What you will feel

• Appetite suppression — usually noticeable by day 7–10. You simply cannot finish your usual portion, and it happens without fighting yourself. You can see the first changes on the scale within 7–10 days.
• Food noise quiets down — intrusive thoughts about eating between meals weaken. You stop opening the fridge “just to look.”
• Mild nausea — occurs in 15–25% of users, especially after fatty meals. Eat slower and in smaller portions — the symptom typically resolves by end of the month.
• Possible constipation — a consequence of slowed GI motility. Fiber and adequate water intake (minimum 2 L per day) solve the problem.

The scale

Loss: 3–7 lbs (1.5–3 kg). Part of this is water and reduced GI contents; part is real fat tissue loss. Do not expect a straight line: fluctuations of 1 lb between weigh-ins are entirely normal. Weigh yourself once a week under identical conditions — not more often.

Month 2: Gaining Momentum (Weeks 5–8)

What changes

Dose typically increases to 5 mg (tirzepatide) or 2–4 mg (retatrutide). Satiety mechanisms stabilize, the body moves past the adaptation phase, and GI side effects fade for most users.

What you will feel

• Portions have shrunk 30–40% from baseline — without willpower. You physically cannot eat as much as before.
• Cravings for sugar and fatty food fade. Many report fast food, chips, and pastries losing their appeal — not because of willpower, but because of absent desire.
• Steadier energy: fewer post-lunch crashes, more even alertness throughout the day.
• Sleep may improve — especially if starting weight contributed to sleep-disordered breathing.

The scale

Cumulative loss: 9–13 lbs (4–6 kg) from start. The pace accelerates to 1.7–2.6 lbs (0.8–1.2 kg) per week. Clothes fit looser — waist circumference drops faster than the scale shows, because visceral fat leaves first. If you carry weight in your midsection, this is where you will see the earliest visible changes.

Month 3: The Turning Point (Weeks 9–12)

Why month three matters most

By now the dose reaches therapeutic range (7.5–10 mg tirzepatide; 4–8 mg retatrutide). Metabolic adaptation has not yet compensated for the caloric deficit — fat loss velocity is at its peak. This is the window when the body releases fat with the least resistance.

What you will feel

• Other people start noticing the change and asking what you have been doing.
• Improvements in blood pressure, fasting glucose, and lipid panels — if tracking labs, the change is statistically significant by now.
• Mobility increases: stairs feel easier, joints bear less load.
• 92% of trial participants continued through this point — side effects have fully resolved for the majority, leaving only the positive effect.

The scale

Cumulative loss: 22–31 lbs (10–14 kg), or 10–15% of starting body weight. SURMOUNT-1 data showed roughly 12% body weight reduction at week 12 on the 10 mg dose. By month 3, average loss reaches 12–15% of body weight — and that objectively changes quality of life: less shortness of breath, normalized blood pressure, improved self-image.

This is the checkpoint that determines whether to continue. If loss is below 5% at week 12, discuss dose adjustment with a physician or consider switching to retatrutide with its triple-agonist mechanism, which can break through resistance.

Months 4–6: Steady-State Decline (Weeks 13–24)

Trajectory

The pace slows — this is physiology, not a plateau. The body adapts to its new weight: basal metabolic rate decreases, and movement becomes less energy-expensive (you are carrying less mass). Normal velocity is 1–1.7 lbs (0.5–0.8 kg) per week. This is still an excellent rate — it just looks less dramatic compared to the first three months.

How to maximize results

• Add resistance training 2–3 times per week. Peptides reduce fat, but without load, lean mass declines too. Losing muscle means lower metabolic rate and a soft-looking body instead of a toned one. Weight training preserves muscle and creates that “toned” look.
• Prioritize protein: 1.2–1.6 g per kg of target weight daily. With suppressed appetite this takes deliberate planning — protein shakes, cottage cheese, eggs, and fish become dietary staples.
• Stay hydrated — slowed GI motility increases constipation risk. Minimum 2 liters per day; consider adding electrolytes.
• Moderate cardio — walking 8,000–10,000 steps per day creates additional deficit without stressing the body.

The scale

Cumulative loss by month 6: 35–49 lbs (16–22 kg), or 18–22% of starting body weight. In SURMOUNT-1, average loss on the maximum tirzepatide dose exceeded 20% at 24 weeks. Retatrutide Phase II showed up to 24% at 24 weeks — currently the best result among all weight-loss peptides.

Months 7–9: Consolidation Phase

What happens

The weight loss curve plateaus for most users. This is not failure — it is the point where energy expenditure equals intake at the current dose. The body has found a new equilibrium, and shifting it further requires additional levers.

Breakthrough strategy

• Discuss with your physician: dose escalation (if headroom remains), switching to retatrutide with its triple mechanism, or locking in current results.
• Adopt 16:8 intermittent fasting — it synergizes with peptide action. A restricted eating window enhances morning fat oxidation without additional effort.
• Run labs regularly: TSH, vitamin D, iron, B12, ferritin. Deficiencies during prolonged caloric restriction are common, and they themselves slow metabolism.
• Recalculate calories: your new weight may require an updated daily intake target. Basal metabolic rate calculators can help.

The scale

Cumulative loss: 44–60 lbs (20–27 kg). Further decline is slow — 0.4–1.1 lbs (0.2–0.5 kg) per week. But visual changes continue: the body redistributes composition even at a stable weight (especially if you are training).

Months 10–12: Maintenance & Exit Strategy

The real challenge

Keeping it off. This is not a figure of speech — 72-week trial data is clear: after discontinuing tirzepatide, patients regain roughly 50% of lost weight within the following 12 months. This is not a drug rebound and not dependency — it is the return of baseline appetite and neuroendocrine signals that regulate body mass.

Exit strategy

...